Viridian Therapeutics, Inc.DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30260% above fair value
$29.96−1.48 (-4.71%)
Close on Nov 20, 2026Market cap $3.39BP/E –Yield –
Viridian Therapeutics, Inc.DE revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Viridian Therapeutics, Inc.DE's revenue for the twelve months ending Jun 30, 2026 was $71.13M, up 23220.3% year over year. For fiscal 2025 it was $70.85M, up 23359.9% from the year before. Over ten years it grew 39.5% a year on average. The highest annual figure on record is $70.85M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.85M | +23359.9% |
| FY2024 | Dec 31, 2024 | $302.00K | -3.8% |
| FY2023 | Dec 31, 2023 | $314.00K | -82.3% |
| FY2022 | Dec 31, 2022 | $1.77M | -40.2% |
| FY2021 | Dec 31, 2021 | $2.96M | +182.2% |
| FY2020 | Dec 31, 2020 | $1.05M | -76.5% |
| FY2019 | Dec 31, 2019 | $4.46M | -46.8% |
| FY2018 | Dec 31, 2018 | $8.39M | +109.5% |
| FY2017 | Dec 31, 2017 | $4.00M | +15.1% |
| FY2016 | Dec 31, 2016 | $3.48M | +37.0% |
| FY2015 | Dec 31, 2015 | $2.54M | -60.9% |
| FY2014 | Dec 31, 2014 | $6.48M | +18.1% |
| FY2013 | Dec 31, 2013 | $5.49M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $284.00K | +278.7% |
| Q1 FY2026 | Mar 31, 2026 | $141.00K | +95.8% |
| Q4 FY2025 | Dec 31, 2025 | $132.00K | +83.3% |
| Q3 FY2025 | Sep 30, 2025 | $70.57M | +81958.1% |
| Q2 FY2025 | Jun 30, 2025 | $75.00K | +4.2% |
| Q1 FY2025 | Mar 31, 2025 | $72.00K | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | $72.00K | 0.0% |
| Q3 FY2024 | Sep 30, 2024 | $86.00K | +19.4% |
| Q2 FY2024 | Jun 30, 2024 | $72.00K | 0.0% |
| Q1 FY2024 | Mar 31, 2024 | $72.00K | -26.5% |
| Q4 FY2023 | Dec 31, 2023 | $72.00K | -31.4% |
| Q3 FY2023 | Sep 30, 2023 | $72.00K | -94.0% |
| Q2 FY2023 | Jun 30, 2023 | $72.00K | -71.9% |
| Q1 FY2023 | Mar 31, 2023 | $98.00K | -54.6% |
| Q4 FY2022 | Dec 31, 2022 | $105.00K | -50.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.20M | +474.5% |
| Q2 FY2022 | Jun 30, 2022 | $256.00K | -76.5% |
| Q1 FY2022 | Mar 31, 2022 | $216.00K | -85.1% |
| Q4 FY2021 | Dec 31, 2021 | $214.00K | +296.3% |
| Q3 FY2021 | Sep 30, 2021 | $208.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $1.09M | +548.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.45M | +75.2% |
| Q4 FY2020 | Dec 31, 2020 | $54.00K | -93.9% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $168.00K | -93.3% |
| Q1 FY2020 | Mar 31, 2020 | $828.00K | +122.6% |
| Q4 FY2019 | Dec 31, 2019 | $880.00K | +84.9% |
| Q3 FY2019 | Sep 30, 2019 | $695.00K | -26.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.51M | +15.2% |
| Q1 FY2019 | Mar 31, 2019 | $372.00K | -92.2% |
| Q4 FY2018 | Dec 31, 2018 | $476.00K | -60.1% |
| Q3 FY2018 | Sep 30, 2018 | $944.00K | -42.1% |
| Q2 FY2018 | Jun 30, 2018 | $2.18M | +203.9% |
| Q1 FY2018 | Mar 31, 2018 | $4.78M | +935.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.19M | +134.2% |
| Q3 FY2017 | Sep 30, 2017 | $1.63M | +74.3% |
| Q2 FY2017 | Jun 30, 2017 | $718.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $462.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $509.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $936.00K | – |
See a number that looks wrong?